Arrowhead Pharmaceuticals, Inc. (ARWR) Stock Overview
Explore Arrowhead Pharmaceuticals, Inc.’s financial performance, market position, analyst ratings, and future outlook.
Arrowhead Pharmaceuticals, Inc. (ARWR)
Key Financials
Key Financials
Market Cap
11.4B
P/E Ratio
-36.85
EPS (TTM)
$-2.25
ROE
-0.61%
ARWR Stock Analysis & Investment Overview (NASDAQ)
Our AI-powered analysis of Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) gives investors deep insight into how the stock performs on the NASDAQ exchange, its growth potential, and its market positioning. With a Meyka AI Score of B+, Arrowhead Pharmaceuticals, Inc.'s NASDAQ-listed shares demonstrate moderate investment characteristics based on our machine learning models.
The current technical analysis of ARWR on the NASDAQ shows an RSI of 38.67, suggesting the stock is in a a neutral condition. Our forecasting models predict a 12-month price target of $112.52 for the NASDAQ listing.
Key metrics behind Arrowhead Pharmaceuticals, Inc.'s NASDAQ-traded stock include a P/E ratio of -36.85 and a market capitalization of 11.4B. Combined with our AI analysis, these give both institutional and retail investors a clear view of ARWR on the NASDAQ.